|

A Follow-up Study to Evaluate the Safety of ALLO-ASC-DFU in ALLO-ASC-DFU-302 Clinical Trial

RECRUITINGSponsored by Anterogen Co., Ltd.
Actively Recruiting
SponsorAnterogen Co., Ltd.
Started2023-04-25
Est. completion2025-12-31
Eligibility
Age19 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06141811

Summary

This is a follow-up study to evaluate the safety for the subjects with ALLO-ASC-DFU treatment in phase 3 clinical trial (ALLO-ASC-DFU-302) for 24 months

Eligibility

Age: 19 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

1. Subjects who are treated with ALLO-ASC-DFU sheet or Vehicle sheet in phase 3 clinical trial of ALLO-ASC-DFU-302.
2. Subjects who are able to give written informed consent prior to study start and to comply with the study requirements.

Exclusion Criteria:

1\. Subjects who are considered not suitable for the study by the principal investigator.

Conditions2

DiabetesDiabetic Foot Ulcer

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.